Clinical applications of DNA vaccines: Current progress

Clinical Infectious Diseases

Volumn 53, Issue 3, 2011, Pages 296-302

  Ferraro, Bernadette ^a   Morrow, Matthew P ^a   Hutnick, Natalie A ^a   Shin, Thomas H ^a   Lucke, Colleen E ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PENNVAX B; PLASMID DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE; ZYC 101;

ANTIBODY PRODUCTION; ANTIBODY TITER; B CELL LYMPHOMA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; GENE TARGETING; HEPATITIS B; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOTHERAPY; INFLUENZA; MALARIA; MELANOMA; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEASONAL INFLUENZA; SECONDARY INFECTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS REPLICATION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; VACCINATION; VACCINES, DNA;

EID: 79960750673     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir334     Document Type: Review

References (53)

1. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-154.
2. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-1749. (Pubitemid 23114660)
3. Wang B, Agadjanyan MG, Srikantan V, et al. Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion. AIDS Res Hum Retroviruses 1993; 9:849-860. (Pubitemid 24017239)
4. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90:11478-11482. (Pubitemid 24008662)
5. MacGregor RR, Boyer JD, Ugen KE, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92-100. (Pubitemid 28328080)
6. Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282:476-480. (Pubitemid 28483675)
7. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008; 9:776-788.
8. Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated NA vaccine against influenza. Expert Rev Vaccines 2009; 8:1205-1220.
9. Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD81 T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000; 19:764-778.
10. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 2006; 31:255-262. (Pubitemid 37162798)
11. Lisziewicz J, Calarota SA, Lori F. The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin Biol Ther 2007; 7:1563-1574. (Pubitemid 47603082)
12. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987; 78:1319-1321. (Pubitemid 18038276)
13. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991; 1088:131-134.
14. Rosati M, Valentin A, Jalah R, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008; 26:5223-5229.
15. Hirao LA, Wu L, Khan AS, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112-3120.
16. Otten G, SchaeferM,Doe B, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004; 22:2489-2493. (Pubitemid 38757348)
17. Hirao LA, Wu L, Satishchandran A, et al. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther 2010; 18:1568-1576.
18. Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28:2565-2572.
19. Boyer JD, Robinson TM, Kutzler MA, et al. SIV DNA vaccine coadministered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005; 34:262-270. (Pubitemid 41179588)
20. Xin KQ, Hamajima K, Sasaki S, et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999; 17:858-866. (Pubitemid 29074740)
21. Egan MA, Chong SY, Megati S, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 21:629-643. (Pubitemid 41113651)
22. Morrow MP, Yan J, Pankhong P, et al. Unique Th1/Th2 phenotypes induced during priming and Memory Phases using IL-12 or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010; 17:1493-1499.
23. Morrow MP, Yan J, Pankhong P, et al. IL-28B/IFN-lambda3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010; 18:1714-1723.
24. Lai L, Vodros D, Kozlowski PA, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007; 369:153-167. (Pubitemid 350030833)
25. Loudon PT, Yager EJ, Lynch DT, et al. GM-CSF increases mucosal and Systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the Epidermis of non-human primates. PLoS One 2010; 5:e11021.
26. Robinson HL, Montefiori DC, Villinger F, et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Vaccine 2006; 352:285-294. (Pubitemid 44215994)
27. Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med 2010; 363:2036-2044.
28. Sheets RL, Stein J, Manetz TS, et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006; 91:610-619. (Pubitemid 43827313)
29. Ledwith BJ, Manam S, Troilo PJ, et al. Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol (Basel) 2000; 104:33-43.
30. Wang Z, Troilo PJ, Wang X, et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004; 11:711-721. (Pubitemid 38519279)
31. Tavel JA, Martin JE, Kelly GG, et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 2007; 44:601-605. (Pubitemid 46594906)
32. Minor P. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010; 50:560-565.
33. Laddy DJ, Yan J, Kutzler M, et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008; 3:e2517.
34. Wei CJ, Boyington JC, Dai K, et al. Cross. -neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med 2010; 24ra21.
35. NIH Clinical trials database. influenza1dna. Accessed April 2011.
36. Evans K, McElwaine-Johnn H, Sharpe M, et al. DNA vaccination protects against an influenza challenge in a double-blind randomized placebo-controlled phase 1b clinical trial. Vaccine 2009; 27:2506-12.
37. World Health Organization. Cervical cancer incidence and mortality worldwide in 2008. GLOBOCAN. 2008. cancers/cervix.asp. Accessed 10 May 2010.
38. Lin K, Roosinovich E, Ma B, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Immunol Res 2010; 47:86-112.
39. Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell D, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine 2008; 26:5210-5215.
40. Yan J, Reichenbach DK, Corbitt N, et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27:431-440.
41. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticledelivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 2003; 188:916-926. (Pubitemid 36530038)
42. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 2002; 8: 1028-1037. (Pubitemid 34517636)
43. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004; 103:317-326.
44. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV161 cervical intraepithelial neoplasia 2/ 3. Clin Cancer Res 2009; 15:361-367.
45. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671. (Pubitemid 44901996)
46. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
47. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2210.
48. Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:3947-3957.
49. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649. (Pubitemid 44901994)
50. Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999-3007.
51. Safety and effectiveness of HIV-1 DNA plasmid vaccine and HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, circumcised men and male-to-female (MTF) transgender persons who have sex with men 2010. Ad51DNA&rank53. Accessed 12 June 2010.
52. Safety and effectiveness of PENNVAX-B vaccine alone, with Il-12, or IL15 cell, 15 in healthy adults 2010. NIH clinicaltrials.gov. http:// clinicaltrials.gov/ct2/show/NCT00528489. Accessed 10 May 2010.
53. Kraynyak KA, Kutzler MA, Cisper NJ, et al. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine; 28:1942-1951.